HOME >> BIOLOGY >> NEWS
Long-term cancer risk follows stem cell transplant recipients

Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study. Published in the January 1, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population. In addition, cancer risk almost quadruples for patients who were over 40 years old at the time of transplant or for patients who received stem cells from a female donor.

Myeloablative, allogeneic HSCT is an effective standard therapy for specific life-threatening diseases, such as leukemia or myelodysplastic syndrome, for which blood cell lineages (which originate principally in the bone marrow and circulate in the blood) are abnormal. Destroying the patient's own unhealthy stem cells in the bone marrow and replacing them with a compatible donor's stem cells offers the chance of cure for a disease that otherwise has a high mortality rate with non-transplant therapies. While the procedure can be lifesaving, it is associated with serious short-term adverse effects, such as mucostitis, infections, and liver vascular obstruction as well as the potential long-term complication of developing of a second, usually solid cancer.

To estimate the risk and identify risk factors associated with this outcome, Genevieve Gallagher, M.D. and Donna L. Forrest, M.D. of the BC Cancer Agency and the University of British Columbia, retrospectively reviewed the medical records of 926 patients treated with myeloablative stem cell transplants over an 18-year period.

They found that at their institution the 10-year incidence of second cancers in t
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
27-Nov-2006


Page: 1 2

Related biology news :

1. Long-term ulcerative colitis study shows Remicade responders maintained improvement
2. Long-term marijuana smoking leads to respiratory complaints
3. Long-term ocean data confirm fishing puts species in double jeopardy
4. Long-term lead exposure linked to cognitive decline in older adults
5. Long-term changes in experience cause neurons to sprout new long-lasting connections
6. Long-term study shows brain function not impaired by tight diabetes control and hypoglycemia
7. Long-term ecological research should include studies on how social science interacts with ecosystems
8. Long-term memory controlled by molecular pathway at synapses
9. Protein chatter linked to cancer activation
10. Newly created cancer stem cells could aid breast cancer research
11. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: